MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Seres Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$2.42−0.04 (-1.63%)
Close on Oct 19, 2026
- Market cap
- $23.59M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Seres Therapeutics has not reported a dividend
No dividend per share appears in Seres Therapeutics's annual filings since fiscal 2012.